Trial Profile
Interventional, randomized, double-blind, placebo-controlled study of the efficacy and safety of initial administration of 25 mg vortioxetine intravenously with 10 mg/day vortioxetine orally in patients with Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Aug 2020
Price :
$35
*
At a glance
- Drugs Vortioxetine (Primary) ; Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Lundbeck A/S
- 07 Aug 2020 Primary endpoint (Change from baseline (Day 0) to Day 1 (24 h post-infusion) in MADRS-6 subscale score) has not been met, as per Results published in the International Clinical Psychopharmacology
- 07 Aug 2020 Results published in the International Clinical Psychopharmacology
- 28 Aug 2019 Status changed from recruiting to completed.